Profile data is unavailable for this security.
About the company
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.
- Revenue in USD (TTM)0.00
- Net income in USD-100.16m
- Incorporated2017
- Employees88.00
- LocationEdgewise Therapeutics Inc1715 38Th StBOULDER 80301United StatesUSA
- Phone+1 (720) 262-7002
- Fax+1 (302) 636-5454
- Websitehttps://edgewisetx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.83bn | 93.00 | -- | 4.03 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 1.85bn | 436.00 | -- | -- | -- | 5.14 | -1.75 | -1.75 | 4.54 | -- | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.86bn | 383.00 | -- | 2.50 | -- | 63.33 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Ginkgo Bioworks Holdings Inc | 251.46m | -892.87m | 1.95bn | 1.22k | -- | 1.70 | -- | 7.74 | -0.459 | -0.459 | 0.1293 | 0.5482 | 0.1196 | 24.49 | 5.01 | 206,449.10 | -42.47 | -- | -46.17 | -- | 78.52 | -- | -355.08 | -- | 6.11 | -1,703.31 | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.97bn | 112.00 | -- | 3.55 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.98bn | 88.00 | -- | 4.69 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.01bn | 7.70k | -- | -- | 18.87 | 0.805 | -0.5642 | -0.5642 | 11.52 | -0.1381 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 0.8617 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.09bn | 355.00 | -- | 5.82 | -- | 12.78 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Recursion Pharmaceuticals Inc | 44.58m | -328.07m | 2.09bn | 500.00 | -- | 4.43 | -- | 46.84 | -1.57 | -1.57 | 0.2145 | 1.98 | 0.0658 | -- | 15.25 | 89,150.00 | -48.42 | -- | -56.49 | -- | 4.46 | -- | -735.99 | -- | -- | -- | 0.0025 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.09bn | 1.76k | 16.53 | 3.22 | 11.77 | 3.24 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Keros Therapeutics Inc | 151.00k | -152.99m | 2.12bn | 136.00 | -- | 5.62 | -- | 14,016.28 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.12bn | 268.00 | -- | -- | -- | -- | -2.87 | -2.87 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -35.26 | -- | -37.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 19 Jan 2024 | 8.91m | 9.57% |
| Viking Global Investors LPas of 31 Dec 2023 | 6.16m | 6.62% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.70m | 6.12% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 3.49m | 3.75% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 3.11m | 3.34% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.96m | 3.18% |
| Citadel Advisors LLCas of 31 Dec 2023 | 2.58m | 2.77% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 2.55m | 2.74% |
| Deep Track Capital LPas of 31 Dec 2023 | 2.54m | 2.73% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.08m | 2.23% |
